Biochemical and biomechanical conditioning for enhancing personalized mesenchymal stem cell therapies
AssigneeBoard of Regents, The University of Texas System
InventorsAaron B. BAKER, Jason LEE
Life of this patent
Estimating the term…
Abstract
A high-throughput screening system is provided for optimizing the conditioning of patient-specific mesenchymal stem cells using a combinatorial set of biochemical factors, pharmacological inhibitors, and biomechanical forces. Also provided are generalized conditions for performing such conditioning. Cells made by these methods are also provided, in addition to cells having a mixed N endothelial cell/pericyte phenotype. These cells produce angiogenic growth factors and induce vascularization following implantation.
Claims80
A cell comprising both an endothelial phenotype and a pericyte phenotype.
A method of enhancing the combined pericyte/endothelial character of mesenchymal stem cells (MSCs), the method comprising:
- (a) obtaining a starting population of mesenchymal stem cells;
- (b) culturing the mesenchymal stem cells on a flexible surface that allows cell adhesion;
- and
- (c) applying a controlled shear stress/mechanical stretch to the mesenchymal stem cells with a force sufficient to produce a conditioned composition comprising cells having a combined pericyte/endothelial character.
A method for identifying conditions for enhancing mesenchymal stem cell (MSC) therapies for a patient, the method comprising:
- (a) obtaining from the patient a starting population of mesenchymal stem cells (MSCs);
- (b) preparing multiple, separate cultures of the patient's MSCs on flexible surfaces that allow cell adhesion;
- (c) applying a variety of controlled shear stresses/mechanical stretches to each of the MSCs;
- and
- (d) screening the cultured cells for markers of a combined pericyte/endothelial cell phenotype, thereby identifying conditions for enhancing MSC therapies for the patient.
A composition comprising mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype for use in the treatment of a patient.
Use of mesenchymal stem cells (MSCs) having a combined pericyte/endothelial phenotype in the manufacture of a medicament for the treatment of a disease in a patient.
Dependencies are inferred from the claim text.